Sort   by:  
 Page size 
UnknownSubcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
Not available
S-EPMC3776971 | biostudies-literature
UnknownAn Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Not available
S-EPMC8105250 | biostudies-literature
UnknownEstrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.
Not available
S-EPMC10232442 | biostudies-literature
UnknownEvolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
Not available
S-EPMC10187060 | biostudies-literature
UnknownAdjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Not available
S-EPMC4872016 | biostudies-literature
UnknownOptimal Sequencing of Anti-HER2 Therapy.
Not available
S-EPMC4038308 | biostudies-literature
UnknownSubcutaneous Administration of Monoclonal Antibodies in Oncology.
Not available
S-EPMC4078128 | biostudies-literature
UnknownSubcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers.
Not available
S-EPMC4490923 | biostudies-literature
UnknownRole of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Not available
S-EPMC5356512 | biostudies-literature
UnknownEducational inequalities in multimorbidity at older ages: a multi-generational population-based study.
Not available
S-EPMC11293817 | biostudies-literature
Sort   by:  
 Page size